Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
Company Overview
RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies for gastrointestinal, infectious, and oncological diseases. With a focus on late clinical-stage development and patented drug formulations, the company leverages extensive expertise in clinical research, regulatory strategy, and commercial operations to address unmet medical needs.
Core Business and Market Position
RedHill Biopharma excels in advancing therapeutic candidates from concept to market. Its dual approach of improving existing drugs and pioneering new therapeutic candidates has established a robust pipeline. The company’s flagship products include Talicia, a novel treatment for Helicobacter pylori infections, and Aemcolo, targeted for travelers' diarrhea. Alongside these commercially marketed drugs, RedHill is actively advancing a number of clinical-stage programs such as opaganib, a first‐in‐class, orally administered sphingosine kinase-2 selective inhibitor, and several other candidates (RHB-107, RHB-102, RHB-104, RHB-204) aimed at addressing critical indications in oncology, viral infections, radiation protection, and inflammatory diseases.
Research and Development Excellence
Emphasizing rigorous research and robust clinical validation, RedHill’s R&D strategy leverages both internal expertise and strategic collaborations with U.S. government agencies and leading academic institutions. The company’s clinical trials and research programs are designed to meet the rigorous standards expected in the biopharmaceutical industry, enhancing its credibility and establishing its authority in the field. Through its focus on clinical efficacy, safety, and patented drug formulations, RedHill reinforces its commitment to innovative therapies and patient outcomes.
Operational Strengths and Competitive Differentiators
A key strength of RedHill is its experienced management team, which includes seasoned professionals from Israel, the U.S., Canada, and Europe. Their combined expertise in regulatory affairs, commercialization, and transactional experience allows the company to execute cost-efficient strategies while positioning its products favorably in a competitive market. This balanced approach not only strengthens its current market offering but also ensures continuous innovation and resilience in the face of industry challenges.
Investor and Market Relevance
For investors and market analysts, RedHill Biopharma represents a compelling blend of commercial successes and forward-looking clinical development programs. The company’s strategic focus on gastrointestinal and infectious therapies, combined with its robust pipeline and global network of expertise, underscores its value as a differentiated player in the specialty biopharmaceutical sector. Through its comprehensive approach to product development and commercialization, RedHill continues to solidify its position within a competitive and evolving market landscape.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its fourth quarter and full year 2020 financial results on March 18, 2021, during a conference call at 8:30 a.m. EDT. Highlights will include the company's full-year financial performance and ongoing clinical studies, particularly for COVID-19 treatments opaganib and RHB-107, as well as a Phase 3 study for RHB-204 targeting pulmonary nontuberculous mycobacteria disease.
The webcast will be available live on the company's website.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will report its fourth quarter and full year 2020 financial results on March 18, 2021, at 8:30 a.m. EDT.
The company will detail 2020 financial performance, commercial activities, and updates on ongoing clinical studies for COVID-19 treatments (opaganib and RHB-107) and a Phase 3 study of RHB-204 for pulmonary nontuberculous mycobacteria.
The webcast will be available live on the company’s website and for replay for 30 days.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announces its participation in several virtual conferences throughout March 2021. Key events include:
- Sachs Spring Life Sciences Week (March 8-11) featuring Guy Goldberg, Chief Business Officer.
- Barclays Global Healthcare Conference (March 9-11) with CEO Dror Ben-Asher on March 11.
- H.C. Wainwright Global Life Sciences Conference (March 9-10) also with Guy Goldberg.
- 33rd Annual Roth Conference (March 15-17), presentation by Guy Goldberg.
- BIO-Europe Spring Digital Conference (March 22-25) with Adi Frish.
Webcasts will be available on RedHill's website for 30 days.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has completed a public offering of 4,375,000 American Depositary Shares (ADSs) at $8.00 each, raising gross proceeds of $35 million. The offering includes a 30-day option for the underwriter to purchase an additional 656,250 ADSs. The funds will support the company's clinical development, commercialization efforts, and general corporate purposes. H.C. Wainwright & Co. served as the book-running manager for the offering. This offering is part of a previously filed shelf registration with the SEC.
ObvioHealth has announced a hybrid clinical trial for COVID-19 treatment utilizing RedHill Biopharma's RHB-107 (upamostat). The Phase 2/3 study will monitor over 300 symptomatic COVID-19 patients remotely, assessing RHB-107's safety and efficacy. This innovative approach combines digital health technologies with home healthcare to enhance patient monitoring while minimizing hospital visits. RHB-107 is designed to combat emerging viral strains, offering a promising oral therapy option. The trial's unique setup fosters data collection while safeguarding participant health.
RedHill Biopharma Ltd. (Nasdaq: RDHL) announced an increase in its public offering to 4,375,000 American Depositary Shares (ADSs) at $8.00 per ADS, aiming for gross proceeds of $35 million. The offering, managed by H.C. Wainwright & Co., expects to close by March 4, 2021. RedHill will use the funds for clinical development, commercialization, acquisitions, and corporate purposes. An additional 656,250 ADSs may be purchased by the underwriter within 30 days. This offering follows a shelf registration statement effective since August 2019.
RedHill Biopharma (Nasdaq: RDHL) announced an increase in its public offering to 4,375,000 American Depositary Shares (ADSs) at $8.00 per ADS, aiming for gross proceeds of approximately $35 million. Closing is expected on March 4, 2021. The underwriter, H.C. Wainwright & Co., has an option for an additional 656,250 ADSs. Proceeds will support clinical development, commercialization, acquisitions, and general corporate purposes. The offering is being made under a 'shelf' registration statement effective since August 2019.
RedHill Biopharma Ltd (Nasdaq: RDHL) announced a firm commitment underwriting agreement with H.C. Wainwright & Co. for the sale of 1,250,000 American Depositary Shares (ADSs) at $8.00 each, with gross proceeds expected to reach $10 million. The closing is anticipated on or around March 4, 2021, subject to customary conditions. Additionally, there is a 30-day option for the underwriter to purchase up to 187,500 additional ADSs. Proceeds will be used for clinical development, commercialization, and general corporate purposes.
RedHill Biopharma (Nasdaq: RDHL) announced the expansion of its global Phase 2/3 study for opaganib, targeting severe COVID-19, to the U.S. The move follows FDA recommendations after reviewing Phase 2 data. The study, with 464 patients planned across 8 countries, is over 50% enrolled and expected to provide top-line data in Q2 2021. Preliminary results indicate opaganib significantly reduced oxygen requirements and demonstrated a robust safety profile in its Phase 2 study. Opaganib, a novel oral SK2 inhibitor, shows promise against viral variants and additional oncological applications.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered into manufacturing agreements with Cosmo Pharmaceuticals NV to produce Movantik and RHB-204. Movantik is RedHill's top-selling drug in the U.S., designed to treat opioid-induced constipation. RHB-204 is in Phase 3 trials for pulmonary nontuberculous mycobacteria disease, showing significant market potential estimated at over $500 million. The partnership is aimed at enhancing supply chain capabilities and meeting increasing market demands.
FAQ
What is the current stock price of Redhill Biopharm (RDHL)?
What is the market cap of Redhill Biopharm (RDHL)?
What is the primary focus of RedHill Biopharma?
Which products does RedHill currently commercialize?
What are some of the key clinical programs in RedHill's pipeline?
How does RedHill differentiate itself in the biopharmaceutical industry?
Why is RedHill considered an expert in clinical-stage drug development?
What makes RedHill Biopharma attractive to investors?
